Arba Minch Hospital, Arba Minch, Ethiopia.
PLoS One. 2010 Oct 11;5(10):e13268. doi: 10.1371/journal.pone.0013268.
Previous studies showed higher early mortality rates among patients treated with antiretroviral drugs in settings with limited resources. One of the reasons was late presentation of patients to care. With improved access to HIV services, we expect improvements in disease stage at presentation. Our objective was to assess the effect of improved availability of HIV services on patient presentation to care and subsequent pre-ART and on-ART outcomes.
At Arba Minch Hospital in Ethiopia, we reviewed baseline characteristics and outcomes of 2191 adult HIV patients. Nearly a half were in WHO stage III at presentation. About two-thirds of the patients (1428) started ART. Patients enrolled in the early phase (OR = 4.03, 95% CI 3.07-5.27), men (OR = 1.78, 95%CI 1.47-2.16), and those aged 45 years and above (OR = 2.04, 95%CI 1.48-2.82) were at higher risk of being in advanced clinical stage at presentation. The pre-treatment mortality rate was 13.1 per 100 PYO, ranging from 1.4 in the rapid scale-up phase to 25.9 per 100 PYO in the early phase. A quarter of the patients were lost to follow-up before starting treatment. Being in less advanced stage (HR = 1.9, 95% CI = 1.6, 2.2), being in the recent cohort (HR = 2.0, 95% CI = 1.6, 2.6), and rural residence (HR = 1.8, 95% CI = 1.5, 2.2) were independent predictors of pre-ART loss to follow-up. Of those who started ART, 13.4% were lost to follow-up and 15.4% died. The survival improved during the study. Patients with advanced disease, men and older people had higher death rates.
Patients started to present at earlier stages of their illness and death has decreased among adult HIV patients visiting Arba Minch Hospital. However, many patients were lost from pre-treatment follow-up. Early treatment start contributed to improved survival. Both pre-ART and on-ART patient retention mechanisms should be strengthened.
先前的研究表明,在资源有限的环境中,接受抗逆转录病毒药物治疗的患者早期死亡率较高。其中一个原因是患者就诊时间较晚。随着获得艾滋病毒服务的机会增加,我们预计患者就诊时的疾病阶段会有所改善。我们的目的是评估改善艾滋病毒服务的可及性对患者就诊和随后的抗逆转录病毒前治疗(ART)和 ART 期间的结果的影响。
在埃塞俄比亚的阿尔巴明奇医院,我们回顾了 2191 名成年艾滋病毒患者的基线特征和结果。近一半患者在就诊时处于世卫组织 III 期。大约三分之二的患者(1428 名)开始接受 ART。在早期阶段入组的患者(OR=4.03,95%CI 3.07-5.27)、男性(OR=1.78,95%CI 1.47-2.16)和 45 岁及以上的患者(OR=2.04,95%CI 1.48-2.82)在就诊时处于更晚期临床阶段的风险更高。治疗前死亡率为每 100 个预期寿命年(PYO)13.1 例,从快速扩展阶段的 1.4 例到早期阶段的每 100 PYO 25.9 例。四分之一的患者在开始治疗前失访。处于较不晚期(HR=1.9,95%CI=1.6,2.2)、处于最近队列(HR=2.0,95%CI=1.6,2.6)和农村居住(HR=1.8,95%CI=1.5,2.2)是治疗前失访的独立预测因素。开始接受 ART 的患者中,13.4%失访,15.4%死亡。在研究期间,生存率有所提高。晚期疾病、男性和老年人的死亡率较高。
在前往阿尔巴明奇医院就诊的成年艾滋病毒患者中,患者开始在疾病的早期阶段就诊,死亡率有所下降。然而,许多患者在治疗前随访中失访。早期治疗开始有助于提高生存率。应加强抗逆转录病毒前和抗逆转录病毒期间的患者保留机制。